Presented significant new data on Contrave at the American Diabetes Association 70th Scientific Sessions, including: Results from a 24-week open-label study demonstrating that treatment with Contrave reduced depression scores and body weight in overweight and obese patients with major depression; andResults from the COR-Diabetes trial demonstrating that Contrave significantly lowers weight and improves blood glucose control in overweight and obese patients with type 2 diabetesntrave NDA filing was accepted by FDA and assigned a Prescription Drug User Fee Act (PDUFA) action date of January 31, 2011.Date for FDA Division of Metabolic and Endocrine Drug Products Advisory Committee meeting was tentatively set for December 7, 2010 to review the Company's NDA for Contrave.Published online results of COR-I Phase 3 study of Contrave in The Lancet on July 30, 2010. Published online results of COR-BMOD Phase 3 study of Contrave plus intense diet, exercise and behavior modification in the journal Obesity on June 17, 2010.

SOURCE Orexigen Therapeutics, Inc.